Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The CDK9 inhibitor enitociclib overcomes resistance to BTK inhibition and CAR-T therapy in mantle cell lymphoma

18 Jun 2024

Abstract excerpt

Abstract Inhibitors of Bruton’s tyrosine kinase (BTKi) and chimeric antigen receptor T-cell (CAR-T) therapy targeting CD19 are paradigm-shifting advances in treating patients with aggressive mantle cell lymphoma (MCL). However, clinical relapses following BTKi and CD19-directed CAR-T treatments are a fast-growing medical challenge. Development of novel therapies to overcome BTKi resistance (BTKi-R) and BTKi-CAR-T...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to CAR-T cell therapy research
Share to Chronic Lymphocytic Leukemia Research
Share to Lymphoma Diagnosis and Treatment

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 38886769
DOI: 10.1186/s40364-024-00589-7

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The CDK9 inhibitor enitociclib overcomes resistance to BTK inhibition and CAR-T therapy in mantle cell lymphomaPMID 38886769Read ↗

The HSP90-MYC-CDK9 network drives therapeutic resistance in mantle cell lymphomaSemantic proximity Read ↗

CDK9 INHIBITORS: a promising combination partner in the treatment of hematological malignanciesSemantic proximity Read ↗

CDK9 pharmacological inhibition with PRT2527 has antitumor activity in marginal zone lymphoma models and can improve the effects of BTK, PI3K, and BCL2 inhibitorsSemantic proximity Read ↗

CDK9 inhibition induces epigenetic reprogramming revealing strategies to circumvent resistance in lymphomaSemantic proximity Read ↗

Cyclin-Dependent Kinase 5 Contributes to Bruton’s Tyrosine Kinase Inhibitor Resistance via the IRE1α/XBP1 Axis in Mantle Cell LymphomaSemantic proximity Read ↗

Systematic Kinase Inhibitor Profiling Identifies CDK9 as a Synthetic Lethal Target in NUT Midline CarcinomaSemantic proximity Read ↗

Transcriptional programming drives Ibrutinib-resistance evolution in mantle cell lymphomaSemantic proximity Read ↗

VIP152 is a selective CDK9 inhibitor with pre-clinical in vitro and in vivo efficacy in chronic lymphocytic leukemiaSemantic proximity Read ↗

Targeting CDK9 with selective inhibitors or degraders in tumor therapy: an overview of recent developmentsSemantic proximity Read ↗

ERBB4-Mediated Signaling Is a Mediator of Resistance to PI3K and BTK Inhibitors in B-cell Lymphoid NeoplasmsSemantic proximity Read ↗

Longitudinal single-cell profiling reveals molecular heterogeneity and tumor-immune evolution in refractory mantle cell lymphomaSemantic proximity Read ↗

Cell-cycle reprogramming for PI3K inhibition overrides a relapse-specific C481S BTK mutation revealed by longitudinal functional genomics in mantle cell lymphoma.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.